Pathogenesis of viral hepatitis

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 2, 2003, Pages 115-119

  Guidotti, Luca G ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Chemokines; Chimpanzees; Cytokines; Cytotoxic T cells; HBV; HCV; Matrix metalloproteinases; Neutrophils; Transgenic mice

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GALACTOSYLCERAMIDE; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; VIRUS DNA; VIRUS RNA;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; HEPATITIS B; HEPATITIS C; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INTERFERON PRODUCTION; LIVER DISEASE; MEDICAL RESEARCH; MOUSE; NONHUMAN; PATHOGENESIS; VIRUS HEPATITIS; VIRUS INHIBITION;

ANIMALIA; DNA VIRUSES; HEPATITIS B VIRUS; HEPATITIS C VIRUS; MUS MUSCULUS; PAN (APE);

EID: 0141504932     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Guidotti LG, Matzke B, Schaller H, Chisari FV. High level hepatitis B virus replication in transgenic mice. J Virol 1995; 69: 6158-69.
2. Guidotti LG, Rochford R, Chung L, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-9.
3. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
4. Guidotti LG, Chisari FV. Cytokine-mediated control of viral infections. Virology 2000; 273: 221-7.
5. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91.
6. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of IFN-a/b eliminates viral RNA-containing capsids in HBV transgenic mice. J Virol 2000; 74: 4165-73.
7. Tsui LV, Guidotti LG, Ishikawa T, Chisari FV. Post-transcriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci USA 1995; 92: 12398-402.
8. McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000; 74: 2255-64.
9. Guidotti LG, McClary H, Moorhead Loudis J, Chisari FV. Nitric oxide inhibits hepatitis B virus replication in the liver of transgenic mice. J Exp Med 2000; 191: 1247-52.
10. Guidotti LG, Borrow P, Hobbs MV, et al. Viral cross talk: Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci USA 1996; 93: 4589-94.
11. Cavanaugh VJ, Guidotti LG, Chisari FV. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in HBV transgenic mice. J Virol 1998; 72: 2630-7.
12. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in HBV transgenic mice. J Virol 1997; 71: 3236-43.
13. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo (in process citation). J Exp Med 2000; 192: 921-30.
14. Kakimi K, Lane TE, Chisari FV, Guidotti LG. Cutting edge: Inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J Immunol 2001; 167: 6701-5.
15. Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
16. Ando K, Guidotti LG, Wirth S, et al. Class I restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol 1994; 152: 3245-53.
17. Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178: 1541-54.
18. Kakimi K, Lane TE, Wieland S, et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001; 194: 1755-66.
19. Sitia G, Isogawa M, Kakimi K, Wieland SF, Chisari FV, Guidotti LG. Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci USA 2002; 99: 13717-22.
20. Kanto T, Hayashi N, Takehara T, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999; 162: 5584-91.
21. Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001; 97: 3171-6.
22. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.
23. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99: 15661-8.
24. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-406.